30,39–41) Lamhamedi-Cherradi et al. employed enzalutamide and androgen receptor-directed antisense oligonucleotides (AR-ASO) to inhibit DSRCT cell growth induced by 5α-dihydrotestosterone, significantly decreasing xenograft tumor burden and highlighting the efficacy of androgen-targeted therapies.42). This evidence concerns the gene AR and neoplasm.